ClinicalTrials.gov
public full text
Public Domain
A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
This is a randomized, double-blind, three-arm, parallel-group study designed to demonstrate the similarity of the pharmacokinetics (PK), safety, and immunogenicity of GS101 injection compared with U.S. commercial Dupixent® and CN commercial Dupixent® in healthy adult participants in China. A total of 294 healthy male adult participants, with 98 participants per treatment group across 3 groups.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Single-Dose Study of MT203#1244170
- A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat#1060263
- CKD-841 Pharmacokinetic/Pharmacodynamic Study#982088
- Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients#1262812
- Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953#1152809
Record · ID 1212271
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive